We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.8B
AUM Growth
-$577M
Cap. Flow
-$347M
Cap. Flow %
-3.21%
Top 10 Hldgs %
77.46%
Holding
139
New
12
Increased
27
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$517M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$232M
3
DBVT
DBV Technologies
DBVT
+$142M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$66.6M
5
NGNE icon
Neurogene
NGNE
+$63.9M

Top Sells

Rank Stock Value
1
XOMA
Xoma
XOMA
+$57M
2
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$29.2M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.1M
4
OMER icon
Omeros
OMER
+$9.78M
5
DYAX
DYAX CORPORATION
DYAX
+$8.72M

Sector Composition

Rank Sector Weight
1 Healthcare 74.03%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$1.47B
$10.7M 0.1%
872,072
– –
IOVA icon
52
Iovance Biotherapeutics
IOVA
$2.08B
$10.5M 0.1%
1,817,429
– –
ARCT icon
53
Arcturus Therapeutics
ARCT
$162M
$9.9M 0.09%
234,267
-21,429
-8% -$1.13M
AKTX
54
Akari Therapeutics
AKTX
$14.5M
$9.5M 0.09%
+495
New +$5.86M
CNCE
55
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$9.31M 0.09%
495,908
– –
OSIR
56
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$9.22M 0.09%
499,193
– –
GBT
57
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.43M 0.08%
+200,000
New +$9.44M
ASND icon
58
Ascendis Pharma A/S
ASND
$16.7B
$7.71M 0.07%
435,540
+335,540
+336% +$6.53M
MGNX icon
59
MacroGenics
MGNX
$238M
$7.45M 0.07%
347,776
+42,733
+14% +$1.34M
AGIO icon
60
Agios Pharmaceuticals
AGIO
$2.1B
$7.06M 0.07%
100,000
– –
DERM
61
DELISTED
Dermira, Inc.
DERM
$6.42M 0.06%
275,000
+175,000
+175% +$4.25M
AIMT
62
DELISTED
Aimmune Therapeutics
AIMT
$6.33M 0.06%
+250,000
New +$5.84M
NDRM
63
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$6.3M 0.06%
305,000
+55,000
+22% +$1.13M
LGND icon
64
Ligand Pharmaceuticals
LGND
$5.8B
$6.29M 0.06%
117,638
– –
ECYT
65
DELISTED
Endocyte, Inc. Common Stock
ECYT
$6.21M 0.06%
+1,356,552
New +$7.1M
ARWR icon
66
Arrowhead Research
ARWR
$12B
$5.82M 0.05%
1,009,509
– –
AERI
67
DELISTED
Aerie Pharmaceuticals
AERI
$5.31M 0.05%
299,356
– –
RXDX
68
DELISTED
Ignyta, Inc.
RXDX
$5.01M 0.05%
571,000
– –
TRVN
69
DELISTED
Trevena, Inc.
TRVN
$4.66M 0.04%
+720
New +$3.55M
SAGE
70
DELISTED
Sage Therapeutics
SAGE
$4.44M 0.04%
105,000
– –
CMRX
71
DELISTED
Chimerix, Inc.
CMRX
$4.4M 0.04%
115,216
– –
AMRN
72
Amarin Corp
AMRN
$302M
$4.26M 0.04%
110,286
– –
SRRA
73
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.1M 0.04%
+5,000
New +$5.64M
CRIS icon
74
Curis
CRIS
$9.74M
$4.04M 0.04%
1,000
+461
+86% +$2.61M
TARA icon
75
Protara Therapeutics
TARA
$215M
$3.82M 0.04%
6,865
+2,446
+55% +$1.51M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Baker Bros. Advisors held 139 positions worth $10.8B, down 5.1% from $11.4B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $347M in Q3 2015, closing 6 positions and reducing 8 holdings. Its most notable exit was Xoma, an estimated $57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 72% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in MEDIVATION, INC. worth $28M.

  • Baker Bros. Advisors's largest Q3 2015 buy was MEDIVATION, INC.: 659,752 shares worth $28M.
  • Baker Bros. Advisors added most to Incyte in Q3 2015, an estimated $517M increase.
  • Baker Bros. Advisors's biggest Q3 2015 reduction was Alder Biopharmaceuticals, cutting an estimated $16.1M.
  • Baker Bros. Advisors fully exited Xoma in Q3 2015, selling an estimated $57M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $10.8B portfolio in Q3 2015.
  • Baker Bros. Advisors opened 12 new positions and closed 6 in Q3 2015.
  • Baker Bros. Advisors's portfolio value fell 5.1% quarter-over-quarter to $10.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.